Pharma: Clinic Roundup
Tuesday, June 18, 2013
Ipsen SA, of Paris, relased results of an international Phase IIIB study, PRIMARYS, assessing an investigational use of Somatuline Autogel (lanreotide) 120 mg as first-line therapy in newly diagnosed acromegaly patients with a macroadenoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.